Pinsent Masons collaborates with LifeArc on expert paper to support drug repurposing

15 Jun 2021 | 01:32 pm | 2 min. read

Multinational law firm Pinsent Masons has collaborated with medical research charity LifeArc, on a new report offering expert advice, insights and practical tips to charities, researchers and funders hoping to repurpose drugs for other – often rare and fatal – conditions.

The pandemic has placed drug repurposing high on the agenda, with medications such as the steroid dexamethasone and rheumatoid arthritis treatment tocilizumab being used to treat patients severely ill with Covid-19.

Charities and patient groups seeking treatments for rare diseases are often particularly interested in the potential of new uses for existing drugs because they offer the possibility of lower overall costs and shorter timeframes to get treatments to patients and licensed medications already have known safety profiles.

The guide, Repurposing medicines: the opportunity and the challenges was launched today at the Findacure's virtual Drug Repurposing for Rare Diseases Conference 2021 and has a range of practical tips and advice for overcoming potential barriers including:

  • Seeking scientific advice from the regulator

  • Developing an intellectual property strategy

  • Collaborating with industry on drug repurposing opportunities

  • Taking steps to ensure medicines are made available to patients

Commenting on the report LifeArc CEO Dr Melanie Lee, CBE said:

The pandemic has shown what is possible in the field of drug repurposing. However, we know that not–for–profits and researchers can be confused by the complex commercial and regulatory challenges that repurposing presents. We want to improve awareness of those challenges so that applications for repurposing proceed smoothly – making it more likely that life-changing medicines will reach patients in the clinic. That translational science is LifeArc’s area of expertise – ensuring that successful lab research results in new treatments or therapies for patients as quickly as possible.”

Nicole Jadeja, life sciences partner at Pinsent Masons, said:

“We are delighted to have partnered with LifeArc on this important project and hope that this will provide practical advice to help convert more repurposing projects into new treatments for patients. One thing that really stands out is how important collaboration is in delivering on the promise of repurposing and drawing upon the experiences of the wide range of stakeholders in the guide."

The guide provides clear examples of the benefits of finding new uses for existing medicines including the repurposing of the breast cancer drug tamoxifen for treating X-linked myotubular myopathy (a rare neuromuscular disorder that mainly affects boys), using a vertigo drug as a treatment for certain rare and devastating neurodegenerative diseases and the successful repurposing of a drug called rapamycin which has transformed the lives of women with lymphangioleiomyomastosis (LAM).

Findacure CEO Dr Rick Thompson said:

"In the world of rare diseases, millions of patients live with no treatment. Drug repurposing offers a quick, cheap, accessible and patient-friendly route to develop new treatments for rare diseases, and in recent years the field has grown steadily. However, we must address roadblocks – including a lack of financial incentive for industry and a lack of regulatory knowledge in academia. We can't wait to get working with LifeArc to deliver change. COVID-19 has shown what can be achieved in repurposing with the right funding and government incentives. Now, those benefits must reach the world's 350 million rare disease patients."

Latest press releases

Show me all press releases

Pinsent Masons has advised Tokai Carbon on the sale of its German subsidiary TOKAI ERFTCARBON GmbH

Multinational law firm Pinsent Masons has advised Tokai Carbon Co., Ltd. (“Tokai Carbon”) on the sale of its German subsidiary TOKAI ERFTCARBON GmbH (“TEG”), to Lenbach Equity Opportunities III. GmbH & Co. KG, which is exclusively advised by DUBAG Investment Advisory GmbH (“DUBAG”).

Pinsent Masons advises on Shackleton exit

Multinational law firm Pinsent Masons has advised the shareholders of independent financial advisory and wealth management firm Shackleton, including the private equity buy-and-build specialist Sovereign Capital Partners, on the exit to Lee Equity Partners.

Pinsent Masons named by The Times as a Top 50 Employer for Gender Equality

Multinational law firm Pinsent Masons has been announced by Business in the Community as one of The Times Top 50 Employers for Gender Equality in 2025. This year’s list marks the sixth time that the firm has been recognised for its commitment to embedding gender equality into all levels of the organisation.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons broadens London IP bench with triple partner hire

Multinational law firm Pinsent Masons has today announced the hire of three intellectual property (IP) partners and a legal director to its IP team in London.

Pinsent Masons announces new leadership for Global IP Group and Life Sciences

Pinsent Masons has appointed Judith Krens (Partner, Amsterdam) and Tom Nener (Partner, Birmingham) as co-leads of the Global Intellectual Property (IP) team, and has appointed Charlotte Weekes (Partner, London) as Head of Life Sciences. The appointments come in light of the upcoming departure of Clare Tunstall, the current Head of IP and Life Sciences, who will be leaving the firm in the Autumn.

Pinsent Masons Announces Engagement with V7 Go to Enhance AI Capabilities

Multinational law firm Pinsent Masons has entered into an agreement with AI software firm, V7 Labs, to deploy their new GenAI automation platform, ‘V7 Go’.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.